At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Outcomes and Toxicity of Busulfex as Part of a High Dose Chemotherapy Preparative Regimen in Autologous Hematopoietic Stem Cell Transplantation for Patients With Plasma Cell Myeloma
In Brief
A Phase 2 clinical trial evaluating busulfan, cyclophosphamide, and 1 other intervention for Multiple Myeloma and Plasma Cell Neoplasm. Completed, enrolled 71 participants across 1 site.
Detailed Summary
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. An autologous stem cell transplant may be able to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This phase II trial is studying how well giving busulfan together with cyclophosphamide followed by an autologous stem cell transplant works in treating patients with multiple myeloma.
Study Details
Timeline
Interventions
IV busulfan 0.8 mg/kg every 6 hours x 16 doses
IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0